2015
Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT.
Alagappan M, Pollom E, von Eyben R, Kunz P, Fisher G, Ford J, Poultsides G, Visser B, Norton J, Kamaya A, Columbo L, Koong A, Chang D. Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT. Journal Of Clinical Oncology 2015, 33: 433-433. DOI: 10.1200/jco.2015.33.3_suppl.433.Peer-Reviewed Original ResearchUnresectable pancreatic adenocarcinomaStereotactic body radiotherapyHigh NL ratioPrior radiation therapyOverall survivalBlood cell countStart of treatmentPancreatic adenocarcinomaTumor marker valuesNL ratioResectable diseaseEntire cohortCA 19Univariate analysisRadiation therapyCell countWhite blood cell countTumor marker CA 19Marker valuesLab valuesBorderline resectable diseasePre-treatment CEAMedian overall survivalAbsolute lymphocyte countAbsolute neutrophil count
2014
A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704.
Heestand G, Murphy J, Moughan J, Regine W, Luo J, Graber M, Kunz P, Fisher G, Guha C, Lin B, Mowat R, Gaur R, Buyyounouski M, Chen Y, Chang D, Koong A. A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704. Journal Of Clinical Oncology 2014, 32: 176-176. DOI: 10.1200/jco.2014.32.3_suppl.176.Peer-Reviewed Original ResearchDisease-free survivalMatrix metalloproteinase-7RTOG 9704MMP-7 serum levelsProximity ligation assaySerum samplesBaseline serum specimensBaseline serum samplesResected stage ILevels of CEAPancreatic cancer patientsPancreatic cancer therapyNovel biomarker panelNational Cancer InstituteGEM armImproved OSEligible patientsOS benefitAdjuvant therapyGemcitabine chemotherapySerum levelsCA 19Cancer patientsClinical endpointsPancreatic cancer